newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Reports First Quarter 2023 Financial Results

INBRIJA® (levodopa inhalation powder) Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q1